title: Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
authors.forename: Craig B
authors.initials: CB
authors.lastname: Reeder
authors.forename: Donna E
authors.initials: DE
authors.lastname: Reece
authors.forename: Vishal
authors.initials: V
authors.lastname: Kukreti
authors.forename: Christine
authors.initials: C
authors.lastname: Chen
authors.forename: Suzanne
authors.initials: S
authors.lastname: Trudel
authors.forename: Kristina
authors.initials: K
authors.lastname: Laumann
authors.forename: Joseph
authors.initials: J
authors.lastname: Hentz
authors.forename: Nicholas A
authors.initials: NA
authors.lastname: Pirooz
authors.forename: Jesus G
authors.initials: JG
authors.lastname: Piza
authors.forename: Rodger
authors.initials: R
authors.lastname: Tiedemann
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Mikhael
authors.forename: Peter L
authors.initials: PL
authors.lastname: Bergsagel
authors.forename: Jose F
authors.initials: JF
authors.lastname: Leis
authors.forename: Rafael
authors.initials: R
authors.lastname: Fonseca
authors.forename: Alexander K
authors.initials: AK
authors.lastname: Stewart
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D003520:Cyclophosphamide